Vancouver, British Columbia — October 16, 2025 — Leads & Copy — InMed Pharmaceuticals Inc. (NASDAQ: INM) has appointed John Bathery to its Board of Directors, effective immediately. Bathery brings over 30 years of pharmaceutical industry experience, including 15 years in corporate development and strategic partnerships. He currently serves as Head of Global Business Development Operations & Externalization at Takeda Pharmaceuticals.
Bathery’s background includes evaluating preclinical and early-stage assets, structuring partnerships, and leading global initiatives, which will be relevant as InMed advances its INM-901 program for Alzheimer’s disease and INM-089 program in Age-related Macular Degeneration (AMD) toward clinical readiness.
Additionally, Bryan Baldasare will not stand for re-election at the Company’s December 18, 2025 Annual General Meeting, due to increasing professional obligations.
Andrew Hull, Chairman of the Board of InMed, expressed gratitude to Bryan for his contributions and welcomed John, citing his deal-making expertise and ability to structure partnerships.
Colin Clancy, Vice President, Investor Relations and Corporate Communications, T: +1.604.416.0999, E: ir@inmedpharma.com
Source: InMed Pharmaceuticals
